Annexin A1 as a potential prognostic biomarker for COVID-19 disease: case-control study

Basit Öğe Kaydı
dc.authoridDenizhan Karış / 0000-0002-5976-4107en_US
dc.authorscopusidDenizhan Karış / 56449066200
dc.authorwosidDenizhan Karış / N-5001-2019
dc.contributor.authorÇanacık, Ömer
dc.contributor.authorSabırlı, Ramazan
dc.contributor.authorAltıntaş, Emel
dc.contributor.authorKarslı, Emre
dc.contributor.authorKarış, Denizhan
dc.contributor.authorKaymaz, Buse
dc.date.accessioned2021-07-14T12:27:05Z
dc.date.available2021-07-14T12:27:05Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: Annexin A1 (AnxA1) is an important endogenous glucocoticoid protein that contributes to the suppression of inflammation by limiting the production of neutrophil and proinflammatory cytokines.This study aims to determine the clinical predictivity value of blood AnxA1 levels in patients with mild and severe-critical pneumonia induced by COVID-19. Methods: This study employed a prospective, case-control study design and was conducted at Ankara Training and Research hospital between 10.02.2021 and 15.03.2021. A total of 74 patients (42 of whom had moderate and 32 of whom had severe/critical cases of COVID-19 disease according to WHO guidelines) and 50 non-symptomatic healthy volunteers participated in the study. Blood samples were taken from patients at the time of hospital admission, after which serum was isolated. Following the isolation of serum, AnxA1 levels were evaluated using the Enzyme-Linked Immunosorbent Assay(ELISA) method. Results: The serum AnxA1 level was measured as 25.5 (18.6-38.6)ng/mL in the control group, 21.2 (14.7-32) ng/mL in the moderate disease group, and 14.8 (9.7-26.8)ng/mL in the severe/critical disease group. Serum AnxA1 levels were significantly lower in the severe/critical disease group compared to the control and moderate disease groups (p=0.01 and p=0.0001, respectively). Using ROC analysis, a larger area under the curve (AUC) for the serum AnxA1 levels of the control group (AUC=0.715, 95% CI =0.626-0.803;p=0.0001) was calculated compared to the COVID-19 patient group for the diagnosis of COVID-19 disease. The AnxA1 level was found to be 80% sensitive and 54.1% specific at a cut-off level of 18.5 ng/ml for the diagnosis of COVID-19 disease. Moreover, the AnxA1 level was found to be 69.8% sensitive and 58.1% specific at a cut-off level of 17.2 ng/ml in predicting the need for ICU treatment. Conclusion: AnxA1 levels may be a beneficial biomarker in the diagnosis of COVID-19 pneumonia and in predicting the need for ICU treatment in patients with COVID-19 pneumonia at the time of admission to the emergency department (ED).en_US
dc.identifier.citationCanacik, O., Sabirli, R., Altintas, E., Karsli, E., Karis, D., Kaymaz, B., Tukenmez Sabirli, G., Kurt, Ö., & Koseler, A. (2021). Annexin A1 as a Potential Prognostic Biomarker for COVID-19 Disease: Case-Control Study. International journal of clinical practice, e14606. Advance online publication. https://doi.org/10.1111/ijcp.14606en_US
dc.identifier.doi10.1111/ijcp.14606en_US
dc.identifier.pmid34228870en_US
dc.identifier.scopus2-s2.0-85109919198en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1111/ijcp.14606
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1926
dc.identifier.wosWOS:000673317000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKarış, Denizhan
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal of Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnnexin A1en_US
dc.subjectAdrenal Cortex Hormonesen_US
dc.subjectCOVID-19en_US
dc.subjectPneumoniaen_US
dc.titleAnnexin A1 as a potential prognostic biomarker for COVID-19 disease: case-control studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
69.pdf
Boyut:
1.07 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu